GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (FRA:ITH) » Definitions » Cyclically Adjusted PS Ratio

Nektar Therapeutics (FRA:ITH) Cyclically Adjusted PS Ratio : 0.77 (As of Jun. 06, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-06-06), Nektar Therapeutics's current share price is €1.268. Nektar Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €1.65. Nektar Therapeutics's Cyclically Adjusted PS Ratio for today is 0.77.

The historical rank and industry rank for Nektar Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:ITH' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.23   Med: 8.77   Max: 81.46
Current: 0.71

During the past years, Nektar Therapeutics's highest Cyclically Adjusted PS Ratio was 81.46. The lowest was 0.23. And the median was 8.77.

FRA:ITH's Cyclically Adjusted PS Ratio is ranked better than
88.69% of 504 companies
in the Biotechnology industry
Industry Median: 5.525 vs FRA:ITH: 0.71

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nektar Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.102. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €1.65 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Nektar Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Nektar Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Cyclically Adjusted PS Ratio Chart

Nektar Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.30 9.34 7.01 1.12 0.29

Nektar Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.28 0.30 0.29 0.47

Competitive Comparison of Nektar Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PS Ratio falls into.



Nektar Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Nektar Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.268/1.65
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Nektar Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.102/131.7762*131.7762
=0.102

Current CPI (Mar. 2024) = 131.7762.

Nektar Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.165 100.560 0.216
201409 0.780 100.428 1.023
201412 0.123 99.070 0.164
201503 0.741 99.621 0.980
201506 0.153 100.684 0.200
201509 0.403 100.392 0.529
201512 0.269 99.792 0.355
201603 0.389 100.470 0.510
201606 0.214 101.688 0.277
201609 0.236 101.861 0.305
201612 0.238 101.863 0.308
201703 0.150 102.862 0.192
201706 0.198 103.349 0.252
201709 0.789 104.136 0.998
201712 0.509 104.011 0.645
201803 0.192 105.290 0.240
201806 5.108 106.317 6.331
201809 0.138 106.507 0.171
201812 0.193 105.998 0.240
201903 0.144 107.251 0.177
201906 0.118 108.070 0.144
201909 0.151 108.329 0.184
201912 0.173 108.420 0.210
202003 0.258 108.902 0.312
202006 0.243 108.767 0.294
202009 0.142 109.815 0.170
202012 0.107 109.897 0.128
202103 0.110 111.754 0.130
202106 0.129 114.631 0.148
202109 0.115 115.734 0.131
202112 0.120 117.630 0.134
202203 0.121 121.301 0.131
202206 0.109 125.017 0.115
202209 0.127 125.227 0.134
202212 0.110 125.222 0.116
202303 0.107 127.348 0.111
202306 0.100 128.729 0.102
202309 0.119 129.860 0.121
202312 0.115 129.419 0.117
202403 0.102 131.776 0.102

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nektar Therapeutics  (FRA:ITH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Nektar Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics (FRA:ITH) Business Description

Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Nektar Therapeutics (FRA:ITH) Headlines

No Headlines